natgillin/translations-raw huggingface dataset:
The median time to initiation of cytotoxic chemotherapy was 28.0 months for patients receiving enzalutamide and 10.8 months for patients receiving placebo (HR = 0.350, 95% CI: [0.303, 0.403], p < 0.0001).
Ensalutamiidi saavatel patsientidel oli tsütotoksilise kemoteraapia alustamiseni kulunud aja mediaanväärtus 28,0 kuud ja platseebot saavatel patsientidel 10,8 kuud [HR = 0,350; 95% usaldusintervall: (0,303; 0,403), p < 0,0001].
The median time to loss of PASI-75 response among the patients re-randomized to placebo was 5.1 weeks.
Mediaanne aeg PASI-75 ravivastuse kadumiseni platseeborühma kordusrandomiseeritud patsientidel oli 5,1 nädalat.
The median time to nadir for ≥ Grade 3 neutropenia is 23 (range 8-104) days post first dose of treatment with ONIVYDE.
Mediaanaeg väikseimate väärtusteni ≥ 3. astme neutropeenia korral on 23 päeva (vahemikus 8–104 päeva) pärast ONIVYDE esimest annust.
The median time to onset of a neurologic event in these patients was 12 days.
Mediaanaeg neuroloogiliste nähtude oli tekkeni neil patsientidel 12 päeva.
The median time to onset of a reaction was 1.5 hours (range: 0.02 to 9.3 hours).
Mediaanaeg reaktsiooni alguseni oli 1,5 tundi (vahemik: 0,02 kuni 9,3 tundi).
The median time to onset of colitis was
Koliidi avaldumiseni kulunud mediaanaeg oli
The median time to onset of grade 2 or worse diarrhoea was 9 days.
Keskmine aeg 2. või raskema astme kõhulahtisuse tekkeks oli 9 päeva.
The median time to onset of hyperthyroidism was 1.4 months (range 1 day to 21.9 months).
Hüpertüreoidismi avaldumiseni kulunud mediaanaeg oli 1,4 kuud (vahemik 1 päev kuni 21,9 kuud).
The median time to onset of hypocalcaemia was 28.3 weeks (any grade) and 45.9 weeks (Grade ≥ 3) in the lenvatinib plus everolimus-treated group.
Mediaanne aeg hüpokaltseemia ilmnemiseni oli lenvatiniibi ja everoliimuse rühmas 28,3 nädalat (kõik astmed) ning 45,9 nädalat (≥ 3. aste).
The median time to onset of hypophysitis was 3.7 months (range 1 day to 11.9 months).
Hüpofüsiidi avaldumiseni kulunud mediaanaeg oli 3,7 kuud (vahemik 1 päev kuni 11,9 kuud).
The median time to onset of ILD or ILD-like adverse reactions was 2.7 months (see section 4.4).
Aja mediaan ILD või ILD-laadsete kõrvaltoimete tekkimiseni oli 2,7 kuud (vt lõik 4.4).
The median time to onset of nephritis was
Nefriidi avaldumiseni kulunud mediaanaeg oli
The median time to onset of neurologic event was 9 days.
Mediaanne aeg neuroloogilise tüsistuse ilmnemiseni oli 9 päeva.
The median time to onset of pneumonitis was 3.3 months (range 2 days to 19.3 months).
Pneumoniidi avaldumiseni kulunud mediaanaeg oli 3,3 kuud (vahemik 2 päeva kuni 19,3 kuud).
The median time to onset of rash and diarrhoea was 10 days and 15 days, respectively.
Keskmine aeg lööbe ja kõhulahtisuse tekkeni oli vastavalt 10 ja 15 päeva.
The median time to onset to the first event was 3 days from the start of BLINCYTO treatment initiation.
Mediaanne aeg esimeste nähtude ilmnemiseni oli 3 päeva alates BLINCYTO ravi algusest.
The median time to progression was 186 days (capecitabine + docetaxel) vs.
Keskmine progressioonivaba periood oli vastavalt
The median time to progression was 186 days (capecitabine + docetaxel) vs.
Keskmine progressioonivaba periood oli vastavalt 186 (kapetsitabiin
The median time to progression was 186 days (docetaxel + capecitabine) vs.
Keskmine aeg haiguse progressioonini oli 186 päeva (dotsetakseel + kapetsitabiin) vs.
The median time to progression was 186 days (docetaxel + capecitabine) vs.
Keskmine aeg progresseerumiseni (TTP) oli 186 päeva (dotsetakseel ja kapetsitabiin) versus
The median time to PSA progression per PCWG2 criteria was 11.2 months for patients treated with enzalutamide and 2.8 months for patients who received placebo [HR = 0.169, (95% CI: 0.147, 0.195), p < 0.0001].
PCWG2 kriteeriumide alusel oli ensalutamiidravi saanud patsientidel PSA progressioonini kulunud aja mediaanväärtus 11,2 kuud ja platseebot saanud patsientidel 2,8 kuud [HR = 0,169; (95% usaldusintervall: 0,147; 0,195), p < 0,0001].
The median time to reach Cmax varied between 45 to 90 minutes and was similar or slightly delayed (by 8 to 45 min) compared to the film-coated tablets.
Cmax saavutamiseks kulunud aja mediaanväärtus oli 45...90 minutit ning oli õhukese polümeerikattega tablettidega võrreldes sama või veidi aeglasem (8...45 min võrra).
The median time to reach Cmax varied between 45 to 90 minutes and was similar or slightly delayed (by 8 to 45 min) compared to the film-coated tablets.
Keskmine aeg Cmax–ini jõudmiseks oli vahemikus 45…90 minutit ning oli sarnane või pisut aeglasem (8…45 minuti võrra) võrreldes õhukese polümeerikattega tablettidega.
The median time to reach Cmax varied between 45 to 90 minutes and was similar or slightly delayed (by 8 to 45 min) compared to the film-coated tablets.
Mediaanaeg Cmax saavutamiseni oli 45...90 minutit ja oli õhukese polümeerikattega tablettidega võrreldes sama või veidi pikem (8...45 min võrra).
The median time to recovery of platelet counts above 50,000/mm3 was 14 days.
Trombotsüütide arvu keskmine taastumise aeg väärtuseni üle 50 000 raku/mm3 oli 14 päeva.
The median time to relapse (re-increase of serum albumin corrected serum calcium above 3 mmol/l) was 18-19 days for the 2 mg and 4 mg doses.
Keskmine aeg retsidiivi (albumiini järgi korrigeeritud kaltsiumisisalduse tõus seerumis uuesti üle 3 mmol/l) tekkeks oli annuste 2 mg ja 4 mg puhul 18...19 päeva.
The median time to relapse (re-increase of serum albumin-corrected serum calcium above 3 mmol/l) was 18- 19 days for the 2 mg and 4 mg doses.
Keskmine aeg retsidiivi (albumiini järgi korrigeeritud kaltsiumisisalduse tõus seerumis uuesti üle 3 mmol/l) tekkeks oli annuste 2 mg ja 4 mg puhul 18...19 päeva.
The median time to relapse (re-increase of serum albumin-corrected serum calcium above 3 mmol/l) was 18-19 days for the 2 mg and 4 mg doses.
Keskmine aeg retsidiivi (albumiini järgi korrigeeritud kaltsiumisisalduse jõudmine seerumis uuesti tasemele üle 3 mmol/l) tekkeks oli annuste 2 mg ja 4 mg puhul 18...19 päeva.
The median time to relapse (return of albumin-corrected serum calcium to levels above 3 mmol/l) was 18 - 19 days for the 2 mg and 4 mg doses.
Keskmine aeg retsidiivi tekkeks (albumiini järgi korrigeeritud kaltsiumisisalduse tõus seerumis uuesti üle 3 mmol/l) oli annuste 2 mg ja 4 mg puhul 18...19 päeva.
The median time to relapse in either group could not be estimated due to low percentage of subjects with relapse.
Mediaanaega retsidiivini ei olnud kummaski rühmas võimalik hinnata, sest retsidiiviga isikute protsentuaalne osakaal oli liiga madal.
The median time to resolution was 3 months.
Kõrvaltoime keskmine taandumisaeg oli 3 kuud.
The median time to resolution was 6 months.
Keskmine taandumisaeg oli 6 kuud.
The median time to response in clinical trials was 7.6-11.6 weeks.
Kliinilistes uuringutes oli ravivastuse saabumise keskmine aeg 7,6...11,6 nädalat.
The median time to response was 1 (range: 0.5 to 3.2) month.
Mediaanaeg ravivastuseni oli 1 kuu (vahemikus 0,5 kuni 3,2 kuud).
The median time to response was 1.0 month (range: 0.7-13.4 months).
Keskmine aeg ravivastuseni oli 1,0 kuud (vahemikus 0,7…13,4 kuud).
The median time to response was 3.1 months (95% CI 2.89, 3.65).
Mediaanne aeg ravivastuseni oli 3,1 kuud (95% CI 2,89; 3,65).
The median time to the first flare was delayed in the pooled group receiving belimumab compared to the group receiving placebo (110 vs 84 days, hazard ratio=0.84, p=0.012).
Keskmine aeg esimese ägenemiseni pikenes belimumabi rühmas platseeborühmaga võrreldes (110 vs 84 päeva, riskisuhe=0,84, p=0,012).
The median time to transfusion independence in the lenalidomide 10 mg arm was 4.6 weeks.
Lenalidomiidi 10 mg ravirühmas oli mediaanne aeg sõltumatuseni vereülekannetest 4,6 nädalat.
The median time to transfusion independence was 4.1 weeks.
Mediaanne aeg sõltumatuseni vereülekannetest oli 4,1 nädalat.
The median times for the most relevant boceprevir-resistant variants observed in genotype 1b patients (> 10%) to become undetectable were as follows: I/V170A, 0.46 years; T54A, 0.47 years; V55A, years; A156S, 0.89 years; and T54S, 1.11 years.
Genotüübiga 1b patsientidel täheldatud kõige olulisemate botsepreviiri suhtes resistentsete variantide (> 10%) tuvastamatuks muutumise aja mediaanid olid järgmised: I/V170A-l 0,46 aastat, T54A-l 0,47 aastat, V55A-l 0,83 aastat, A156S-l 0,89 aastat ja T54S-l 1,11 aastat.
The median times to progression in these endpoints ranged from 0.7 to 2.1 months longer for TMZ than for procarbazine (log rank p = < 0.01 to 0.03).
Keskmiselt progresseerus haigus nimetatud näitajateni TMZ rühmas 0,7 kuni 2,1 kuud hiljem kui prokarbasiinil (logaritmiline astak-p = < 0,01...0,03).
The median times to progression in these endpoints ranged from 0.7 to 2.1 months longer for TMZ than for procarbazine (log rank p=< 0.01 to 0.03).
Keskmiselt progresseerus haigus nimetatud näitajateni TMZ-i rühmas 0,7 kuni 2,1 kuud hiljem kui prokarbasiinil (logaritmilise astaku p-väärtus = < 0,01–0,03).
The median treatment duration and daily dose, as well as the rate of dose modification and dose reduction were similar to those observed in patients with a reported PS ≥ 2 receiving placebo (8.3%).
Keskmine ravikestus ja ööpäevane annus, nagu ka annuse kohandamise ja vähendamise määr, sarnanes nende platseebot saanud patsientide andmetega (8,3%) kelle PS oli samuti ≥ 2.
The median treatment duration was 71.8 weeks (range 0.4–258 weeks).
Ravi mediaanne kestus oli 71,8 nädalat (vahemikus 0,4...258 nädalat).
The median treatment duration was 71.8 weeks (range 0.4–258 weeks).
Ravi mediaanne kestus oli 71,8 nädalat (vahemikus 0,4…258 nädalat).
The median TTP was 6.5 months for the VELCADE monotherapy patients compared with 9.3 months for the VELCADE plus pegylated liposomal doxorubicin combination therapy patients.
VELCADE monoteraapiat saanud patsientidel oli TTP mediaanväärtus 6,5 kuud, VELCADE’t koos pegüleeritud liposomaalse doksorubitsiiniga saanud patsientidel aga 9,3 kuud.
The median TTP was 6.9 months for the bortezomib monotherapy patients compared with 8.9 months for the Caelyx plus bortezomib combination therapy patients.
Keskmine TTP bortesomiibi monoteraapiat saanud patsientidel oli 6,9 kuud võrreldes Caelyx’i ja bortesomiibiga kombinatsioonravi saanud patsientide 8,9 kuuga.
The median tyramine dose required to cause an increase in systolic blood pressure of ≥30 mmHg from pre-dose baseline was 325 mg with Sivextro compared to 425 mg with placebo.
Et tõsta süstoolset vererõhku annustamiseelse vererõhuga võrreldes ≥30 mmHg võrra kõrgemale, oli türamiini mediaanannus Sivextroga koos manustamisel 325 mg, samas kui platseebo kasutamisel oli see 425 mg.
The median V/F in patients with weight > 100 kg was approximately 37% higher as compared to patients with weight ≤ 100 kg.
Patsientidel, kelle kehamass oli > 100 kg, oli V/F mediaan ligikaudu 37% võrra suurem kui patsientidel, kelle kehamass oli ≤ 100 kg.
The medical staff will prepare InductOs in the operating room.
Meditsiinitöötajad valmistavad InductOs’e paigaldamiseks ette operatsioonitoas.
The medical term for this condition is Hypoactive Sexual Desire Disorder, also known as HSDD.
Selle haigusseisundi meditsiiniline nimetus on hüpoaktiivne seksuaalse soovi häire, tuntud ka kui HSDD (hypoactive sexual desire disorder).
The medical term for this condition is ‘patent ductus arteriosus’, i.e. an open ductus arteriosus.
Seda seisundit nimetatakse avatud arterioosjuhaks.
The medicated drinking water should be prepared freshly each day.
Iga päev tuleb valmistada värske ravijook.
The medicinal product contains less than 1 mmol sodium (23 mg) per injection, indicating that it is essentially “sodium free”.
See ravim sisaldab vähem kui 1 mmol naatriumi (23 mg) ühe süste kohta, seega on sisuliselt naatriumivaba.
The medicinal product contains methylparahydroxybenzoate (E218) which may cause allergic reactions (possibly delayed), and propylene glycol which may cause skin irritation.
Ravim sisaldab metüülparahüdroksübensoaati (E218), mis võib põhjustada allergilisi reaktsioone (mis võivad tekkida hiljem) ja propüleenglükooli, mis võib põhjustada nahaärritust.
The medicinal product has a rapid onset of action and is effective within 5 minutes of application.
Ravimi toime algab kiiresti – 5 minuti jooksul pärast aplitseerimist.
The medicinal product has been authorised under a so-called "conditional approval" scheme.
Ravimpreparaat on saanud müügiloa tingimusliku heakskiidu alusel.
The medicinal product has only been studied in postmenopausal women.
Ravimi kasutamist on uuritud ainult postmenopausis naistel.
The medicinal product is for subcutaneous use only, do not administer intravenously.
Ravim on ainult subkutaanseks kasutamiseks, ärge manustage seda intravenoosselt.
The medicinal product is supplied in a multidose, colourless 15 mL Type I glass vial, sealed with a chlorobutyl stopper and aluminium seal.
Ravimpreparaat tarnitakse mitmeannuselises värvitus 15 ml I tüüpi klaasist viaalis, mis on suletud klorobutüülist punnkorgi ja alumiiniumkattega.
The medicinal product is to be taken during or right after a feed.
Ravimit tuleb võtta söögi ajal või vahetult pärast seda.
The medicinal product may be stored for a maximum of 28 days up to 30°C and away from direct heat or direct light.
Ravimit võib hoida maksimaalselt 28 päeva temperatuuril kuni 30° C ja otsese kuumuse või valguse eest kaitstult.
The medicinal product may be stored for a maximum of 4 weeks below 30°C and away from direct heat or direct light.
Ravimit võib hoida maksimaalselt 4 nädalat kuni 30C ja otsese kuumuse või valguse eest kaitstult.
The medicinal product may be stored for a maximum of 4 weeks not above 25°C and away from direct heat or direct light.
Ravimit võib hoida maksimaalselt 4 nädalat kuni 25C ja otsese kuumuse või valguse eest kaitstult.
The medicinal product may be stored for a maximum of 4 weeks not above 30°C and away from direct heat or direct light.
Ravimit võib hoida maksimaalselt 4 nädalat kuni 30C ja otsese kuumuse või valguse eest kaitstult.
The medicinal product may be stored for a maximum of 4 weeks not above 30°C and away from direct heat or direct light.
Ravimit võib hoida maksimaalselt 4 nädalat kuni 35C ja otsese kuumuse või valguse eest kaitstult.
The medicinal product must be administered via the subcutaneous route only.
Ravimpreparaati tohib manustada ainult subkutaanselt.
The medicinal product must be used immediately after diluting by aseptic technique
Pärast lahjendamist aseptilisel meetodil tuleb ravim kohe ära kasutada.
The medicinal product should be administered via the subcutaneous route.
Ravimit tuleb manustada subkutaanselt.
The medicinal product should be at room or body temperature before use.
Ravim peab enne kasutamist olema toa- või kehatemperatuuril.
The medicinal product should be discarded before use if it contains particulate matter or is discoloured.
Kui näete lahuses tahkeid osakesi või värvi muutust, siis tuleb ravimpreparaat kasutusest kõrvaldada.
The medicinal product should be used with caution in patients who consume substantial quantities of alcohol.
Ravimit tuleb kasutada ettevaatlikult patsientidel, kes tarbivad alkoholi suurtes kogustes.
The medicinal product should only be administered when material and personnel experienced in evaluating and treating anaphylaxis are immediately available.
Seda ravimit võib manustada ainult juhul, kui anafülaksia hindamiseks ja raviks vajalikud materjalid ja vastavate kogemustega personal on koheselt saadaval.
The medicinal products should be administered sequentially and not mixed in the same infusion bag.
Ravimid tuleb manustada üksteise järel ja neid ei tohi segada samas infusioonikotis.
The medicine also contains sucrose.
Ravim sisaldab ka sahharoosi.
The medicine also increased levels of haemoglobin in the blood and improved the dogs’ physical condition.
Ravim tõstis ka koerte vere hemoglobiinitaset ja parandas nende füüsilist seisundit.
The medicine also produced about 20% more successful vaginal penetrations than placebo.
Ravimi tõttu toimus ka umbes 20% rohkem edukaid vaginaalseid suguühteid kui platseebo puhul.
The medicine can be kept at room temperature (not above 30oC) for up to 3 hours, prior to administration.
Ravimit võib enne manustamist hoida toatemperatuuril (kuni 30°C) kuni 3 tundi.
The medicine can be stored for a single period of 2 months at a temperature not above 25°C, after which it must be discarded.
Ravimit võib hoida 2 kuu jooksul temperatuuril kuni 25 °C; selle aja möödumisel tuleb ravim minema visata.
The medicine can only be obtained by ‘special’ prescription.
Seda ravimit saab üksnes eriretsepti alusel.
The medicine can only be obtained with a prescription and is available as a solution for injection.
ZACTRAN on retseptiravim ja seda turustatakse süstelahusena.
The medicine can only be obtained with a prescription.
Abilify on retseptiravim.
The medicine can only be obtained with a prescription.
Abraxane on retseptiravim.
The medicine can only be obtained with a prescription.
Abseamed on retseptiravim.
The medicine can only be obtained with a prescription.
Actelsar HCT on retseptiravim.
The medicine can only be obtained with a prescription.
Adcetris on retseptiravim.
The medicine can only be obtained with a prescription.
Adenuric on retseptiravim.
The medicine can only be obtained with a prescription.
Advate on retseptiravim.
The medicine can only be obtained with a prescription.
Aerius on retseptiravim.
The medicine can only be obtained with a prescription.
Afinitor on retseptiravim.
The medicine can only be obtained with a prescription.
Aloxi on retseptiravim.
The medicine can only be obtained with a prescription.
Amyvid on retseptiravim.
The medicine can only be obtained with a prescription.
Atriance on retseptiravim.
The medicine can only be obtained with a prescription.
ATryn on retseptiravim.
The medicine can only be obtained with a prescription.
Avastin on retseptiravim.
The medicine can only be obtained with a prescription.
Avonex on retseptiravim.
The medicine can only be obtained with a prescription.
Azomyr on retseptiravim.
The medicine can only be obtained with a prescription.
BeneFIX on retseptiravim.
The medicine can only be obtained with a prescription.
Benlysta on retseptiravim.
The medicine can only be obtained with a prescription.
Betaferon on retseptiravim.
The medicine can only be obtained with a prescription.
Bexsero on retseptivaktsiin.
The medicine can only be obtained with a prescription.
Binocrit on retseptiravim.
The medicine can only be obtained with a prescription.
Bondronat on retseptiravim.
The medicine can only be obtained with a prescription.
Bretaris Genuair on retseptiravim.
The medicine can only be obtained with a prescription.
Brinavess on retseptiravim.
The medicine can only be obtained with a prescription.
Bronchitol on retseptiravim.
The medicine can only be obtained with a prescription.
Buccolam on retseptiravim.
The medicine can only be obtained with a prescription.
Busilvex on retseptiravim.
The medicine can only be obtained with a prescription.
Bydureon on retseptiravim.
The medicine can only be obtained with a prescription.
Caelyx on retseptiravim.
The medicine can only be obtained with a prescription.
Capecitabine Accord on retseptiravim.
The medicine can only be obtained with a prescription.
Capecitabine Medac on retseptiravim.
The medicine can only be obtained with a prescription.
Capecitabine Teva on retseptiravim.
The medicine can only be obtained with a prescription.
Carbaglu on retseptiravim.
The medicine can only be obtained with a prescription.
CellCept on retseptiravim.
The medicine can only be obtained with a prescription.
Celsentri on retseptiravim.
The medicine can only be obtained with a prescription.
Celvapan on retseptivaktsiin.
The medicine can only be obtained with a prescription.
Cetrotide on retseptiravim.
The medicine can only be obtained with a prescription.
Champix on retseptiravim.
The medicine can only be obtained with a prescription.
Cholestagel on retseptiravim.
The medicine can only be obtained with a prescription.
ChondroCelect on retseptiravim.
The medicine can only be obtained with a prescription.
Cialis on retseptiravim.
The medicine can only be obtained with a prescription.
Cimzia on retseptiravim.
The medicine can only be obtained with a prescription.
Cinacalcet Mylan on retseptiravim.
The medicine can only be obtained with a prescription.
Cinryze on retseptiravim.
The medicine can only be obtained with a prescription.
Circadin on retseptiravim.
The medicine can only be obtained with a prescription.
Clopidogrel Acino on retseptiravim.
The medicine can only be obtained with a prescription.
Clopidogrel Apotex on retseptiravim.
The medicine can only be obtained with a prescription.
Clopidogrel BGR on retseptiravim.
The medicine can only be obtained with a prescription.
Clopidogrel HCS on retseptiravim.
The medicine can only be obtained with a prescription.
Clopidogrel Zentiva on retseptiravim.
The medicine can only be obtained with a prescription.
Colobreathe on retseptiravim.
The medicine can only be obtained with a prescription.
Corlentor on retseptiravim.
The medicine can only be obtained with a prescription.
Cotellic on retseptiravim.
The medicine can only be obtained with a prescription.
Crixivan on retseptiravim.
The medicine can only be obtained with a prescription.
Daliresp on retseptiravim.
The medicine can only be obtained with a prescription.
Daxas on retseptiravim.
The medicine can only be obtained with a prescription.
Desloratadine Teva on retseptiravim.
The medicine can only be obtained with a prescription.
Dexdor on retseptiravim.
The medicine can only be obtained with a prescription.
Dit geneesmiddel is uitsluitend op doktersvoorschrift verkrijgbaar.
The medicine can only be obtained with a prescription.
Docefrez on retseptiravim.
The medicine can only be obtained with a prescription.
Docetaxel Accord on retseptiravim.
The medicine can only be obtained with a prescription.
Docetaxel Teva on retseptiravim.
The medicine can only be obtained with a prescription.
Doribax on retseptiravim.
The medicine can only be obtained with a prescription.
Ecalta on retseptiravim.
The medicine can only be obtained with a prescription.
Ecansya on retseptiravim.
The medicine can only be obtained with a prescription.
Edurant on retseptiravim.
The medicine can only be obtained with a prescription.
Eklira Genuair on retseptiravim.
The medicine can only be obtained with a prescription.
Elaprase on retseptiravim.
The medicine can only be obtained with a prescription.
Eliquis on retseptiravim.
The medicine can only be obtained with a prescription.
Emadine on retseptiravim.
The medicine can only be obtained with a prescription.
Enbrel on retseptiravim.
The medicine can only be obtained with a prescription.
Enurev Breezhaler on retseptiravim.
The medicine can only be obtained with a prescription.
Enyglid on retseptiravim.
The medicine can only be obtained with a prescription.
Episalvan on retseptiravim.
The medicine can only be obtained with a prescription.
Epivir on retseptiravim.
The medicine can only be obtained with a prescription.
Esbriet on retseptiravim.
The medicine can only be obtained with a prescription.
Eucreas on retseptiravim.
The medicine can only be obtained with a prescription.
Eurartesim on retseptiravim.
The medicine can only be obtained with a prescription.
Exelon on retseptiravim.
The medicine can only be obtained with a prescription.
Exjade on retseptiravim.
The medicine can only be obtained with a prescription.
Fablyn on retseptiravim.
The medicine can only be obtained with a prescription.
Fabrazyme on retseptiravim.
The medicine can only be obtained with a prescription.
Fampyra on retseptiravim.
The medicine can only be obtained with a prescription.
Faslodex on retseptiravim.
The medicine can only be obtained with a prescription.
Feraccru on retseptiravim.
The medicine can only be obtained with a prescription.
Ferriprox on retseptiravim.
The medicine can only be obtained with a prescription.
Filgrastim Hexal on retseptiravim.
The medicine can only be obtained with a prescription.
Firazyr on retseptiravim.
The medicine can only be obtained with a prescription.
Flixabi on retseptiravim.
The medicine can only be obtained with a prescription.
Forxiga on retseptiravim.